By far, the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or with periodic deterioration. Drug therapy is an important part of the overall treatment of prostate disease. In addition, treatment often ends in failure due to improper treatment, missed drug treatment, and neglect of disease when the condition is remission.
Therefore, 20-30% of patients are dissatisfied with the treatment and do not feel the reduction of symptoms of urinary system diseases and the improvement of quality of life. This is most likely due to incorrect assessment of lower urinary tract function in men with BPH and improper treatment options.
As we all know, prostatitis is divided into acute and chronic (CP), bacterial and bacterial.
prostatitis%
- Acute bacterial prostatitis-5-10%;
- Chronic bacterial prostatitis-6-10%;
- Chronic bacterial prostatitis-80-90%, including prostate pain-20-30%.
The most common is chronic bacterial prostatitis, which must be controlled and promptly prevented from worsening with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5a-reductase inhibitors (finasteride, dutasteride);
- a-blockers (doxazosin, tamsulosin);
- Phytotherapy (sabal palm extract);
- antibiotic;
- Amino acid complex
- Animal organ extract (prostate extract);
- Insect therapy drugs (products from insects).
At the same time, 13-30% of the effects of using a-blockers will not occur within 3 months of treatment-no further use of this group of drugs for treatment is recommended.
When prescribing finasteride, doctors need to be prepared for the most significant side effects of the drug: impotence, decreased libido, and decreased ejaculation can cause patients to withdraw the drug on their own.
The treatment of BPH and prostatitis is an important and unresolved urological problem.
In the absence of indications for prostate surgery, frequent worsening of CP forces doctors to use other methods in drug treatment. Usually, the presence of CP will aggravate the process of BPH, because 80% of inflammation occurs in benign prostatic hyperplasia.
Modern medicine provides us with new opportunities to treat CP and BPH and prevent deterioration.